Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

PURPOSE: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has not been explored. EXPERIMENTAL DESIGN: We identified all patients with metastatic EGFR exon19del or L858R mutant lung cancers treated with f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Offin, Michael, Rizvi, Hira, Tenet, Megan, Ni, Andy, Sanchez-Vega, Francisco, Li, Bob, Drilon, Alexander, Kris, Mark G., Rudin, Charles M., Schultz, Nikolaus, Arcila, Maria, Ladanyi, Marc, Riely, Gregory J., Yu, Helena A., Hellmann, Matthew D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6347551/
https://ncbi.nlm.nih.gov/pubmed/30045933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados